Aethlon Medical To Present at The New York Society of Security Analysts -- Investing in Homeland Security Industry Conference.Business Editors/Health/Medical Writers Topical News: War On Terrorism Terrorist acts and the threat of Terrorism have occupied the various law enforcement agencies in the U.S. government for many years. The Anti-Terrorism and Effective Death Penalty Act of 1996, as amended by the usa patriot act Investing in Homeland Security Industry Conference 2004 SAN DIEGO--(BUSINESS WIRE)--April 13, 2004 Aethlon Medical, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AEMD AEMD Automotive Electric Motor Drive (US Department of Energy program) ) announced today that its Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Mr. James A. Joyce has accepted an invitation to present at the New York Society of Security Analysts' 2004 Investing In The Homeland Security Industry conference, to be held on June 30, 2004 at the Harvard Club in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . "We are honored to have this opportunity to introduce our treatment countermeasures against biological weapons and other infectious diseases to such an esteemed audience of analysts and other professionals from the financial community," stated Mr. Joyce. The New York Society of Security Analysts (NYSSA Nyssa (nĭs`ə), name of several ancient cities devoted to the worship of Dionysus. The best known of them is a town of Cappadocia, Asia Minor, near the Halys (now the Kizil Irmak) River. It was the residence of St. Gregory of Nyssa. ) has educated and inspired investment professionals since 1937, providing them with a unique forum for the exchange of ideas and information. NYSSA's founders included Benjamin Graham, "the father of security analysis" and one of the most influential men in the history of finance. As a not-for-profit educational organization, NYSSA's twin goals are to inform and educate investors; and to advance the professional competence of investment professionals, including security analysts, portfolio managers, investment advisors, and others involved in the investment process. NYSSA's audience is drawn from more than 8,700 members, most of whom are involved in the decision-making process including: -- Securities analysts from brokerage firms and investment banks -- Portfolio managers from pension funds, mutual funds, hedge funds, insurance companies, and endowments & trusts -- Institutional private equity investors -- High net worth investors -- Industry consultants, other investment bankers, attorneys, and accountants About Aethlon Medical Aethlon Medical is pioneering the development of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body. Aethlon has published compelling human blood studies of the Hemopurifier(TM) to treat HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome and Hepatitis-C (HCV HCV abbr. hepatitis C virus HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. ), and most recently, has announced that it is developing pathogen filtration devices to treat infectious agents used in biological warfare and terrorism. The Hemopurifier is a proprietary platform technology that converges the established scientific principles of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. On March 4, 2004, Aethlon announced a cooperative agreement with the National Center for Biodefense (NCBD NCBD National CAHPS Benchmarking Database ) at George Mason University Named after American revolutionary, patriot and founding father George Mason, the university was founded as a branch of the University of Virginia in 1957 and became an independent institution in 1972. . Under the agreement, Aethlon and the NCBD will collaborate to develop pathogen and toxin filtration devices designed to protect the lives of U.S. Military personnel exposed to infectious agents as a result of biological warfare. For additional information, visit the company's Web site at www.AethlonMedical.com. Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion